--- title: "Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR" type: "News" locale: "en" url: "https://longbridge.com/en/news/285095483.md" description: "Kahn Swick & Foti, LLC is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED funds. Shareholders are set to receive $3.16 per share in cash, along with potential milestone payments. The firm aims to assess whether this offer adequately values the company and the process leading to it. Interested parties can contact KSF for more information regarding their legal rights in this transaction." datetime: "2026-05-04T16:00:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285095483.md) - [en](https://longbridge.com/en/news/285095483.md) - [zh-HK](https://longbridge.com/zh-HK/news/285095483.md) --- # Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. \>\>\>CLICK HERE To Learn More. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-espr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn Kahn Swick & Foti, LLC Managing Partner Lewis S. Kahn lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260504965150/en/ ### Related Stocks - [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md) ## Related News & Research - [Esperion cleared for merger by German antitrust authority; stockholder vote set for July 8](https://longbridge.com/en/news/289231651.md) - [Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%](https://longbridge.com/en/news/285820903.md) - [Monashee Investment Management LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR](https://longbridge.com/en/news/289577870.md) - [Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk](https://longbridge.com/en/news/285830726.md) - [Esperion (ESPR) was downgraded to a Hold Rating at Needham](https://longbridge.com/en/news/285108916.md)